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Epithelial carcinoma of the ovary is one of the most common
gynaecologic malignancies, and the fourth most frequent cause of
cancer death in women (Yancik, 1993). The asymptomatic early
stages of ovarian cancer mean that most patients have widespread
disease at the time of diagnosis. Patients with FIGO stage III and
IV disease and significant residual tumour masses after primary
surgery can expect a 5-year survival rate of less than 10%, despite
multiple courses of platinum-based chemotherapy (Omura et al,
1991). 
Until the mid-1990s, the combination of a platinum compound
and an alkylating agent was considered best therapy for these
patients, but a new standard of care emerged after the publication
of trial GOG-111 in 1996 (McGuire et al, 1996) which was
followed by the first reports of the INTERGROUP trial, OV10, in
1998 (Piccart et al, 2000). Both these large, prospective random-
ized studies demonstrated that patients treated with cisplatin-pacli-
taxel in combination had significantly higher response rates,
progression-free survival and overall survival compared with the
previous standard treatment of cisplatin and cyclophosphamide.
However, this higher efficacy was at the expense of greater toxi-
city. In GOG-111, 135 mg/m2 paclitaxel was administered with 75
mg/m2 cisplatin as an inconvenient 24-hour infusion, and neuro-
toxicity in particular was more frequently observed (28% vs 21%,
P ≤ 0.05). Reducing the paclitaxel infusion time to 3 hours (with a
concomitant increase in dose to 175 mg/m2) in OV.10 produced a
further increase in neurotoxicity, with 19.6% patients experiencing
CTC grade III or IV sensory neurotoxicity, compared with 1% of
patients receiving cisplatin-cyclophosphamide. 
Meta-analyses incorporating data on nearly 10 000 patients
from 45 randomized trials suggested that the substitution of carbo-
platin for cisplatin was equally effective either as a single agent or
in combination (Aabo et al, 1998). The addition of carboplatin to
paclitaxel was expected to produce less emesis and neurotoxicity,
but greater myelosuppression compared with cisplatin-paclitaxel.
Seven phase I–II trials of carboplatin-paclitaxel combinations
have been reported, involving 260 chemo-naïve ovarian cancer
patients (Bookman et al, 1996; Lhomme et al, 1996; Bolis et al,
1997; duBois et al, 1997; Huizing et al, 1997; ten Bokkel Huinink
et al, 1997; Siddiqui et al, 1997). Doses of carboplatin ranged from
AUC 5–10, and paclitaxel from 120–250 mg/m2 and almost all
the trials used a 3-hour paclitaxel administration schedule. As
expected the major toxicities in all studies were myelosuppression
and neurotoxicity, however, an apparent reduction in the expected
level of thrombocytopenia was observed in many of these trials,
and an interaction at the megakaryocyte level rather than a phar-
macokinetic interaction is thought to be responsible (Calvert et al,
1995). Antitumour activity was substantial, with response rates
ranging from 70–100%. 
The direct comparison of carboplatin-paclitaxel with cisplatin-
paclitaxel in a prospective, randomized trial as first-line therapy
for advanced ovarian cancer has now been the subject of three
phase III trials (Neijt et al, 1997; duBois et al, 1999; Ozols et al,
1999). 
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The Danish–Dutch study (Neijt et al, 1997) randomized 208
patients with stage IIB–IV disease to receive paclitaxel 175 mg/m2
over 3 hours in combination with either carboplatin AUC 5 or
cisplatin 75 mg/m2. Although this study had relatively few
patients, it suggested that the carboplatin arm was at least as effec-
tive as cisplatin, with better patient tolerance. The level of neuro-
toxicity was reported to be similar in the two arms; only 26%
(carboplatin) and 18% (cisplatin) patients reported no neurologic
symptoms during their chemotherapy. The treatments appeared to
be equally active, with response rates of 70% and 73% respec-
tively for the carboplatin and cisplatin combinations, and median
progression-free survivals of 17 months in both arms. 
Patients in GOG trial 158 differed from the Danish–Dutch study
in that only optimally debulked (to <1 cm residual tumour) stage
III patients were eligible. The reason for this protocol design was
based on concerns from in vitro data and clinical trials in other
tumour types (i.e. testicular germ cell tumours) which suggested
that the substitution of carboplatin for cisplatin for patients with
potentially curable disease could be detrimental to their outlook.
The trial was therefore designed with the hypothesis that changing
cisplatin for carboplatin would decrease the progression free
survival in this potentially curable patient group. Hence, the
choice of the control arm as per the GOG 111 cisplatin-paclitaxel
schedule, versus a study arm of carboplatin AUC 7.5 in combina-
tion with paclitaxel 175 mg/m2 over 3 hours. With 425 and 415
patients randomized to each arm respectively, and a median follow
up of 19 months, the first survival analysis reported no difference
in efficacy (Ozols et al, 1999). A median time to progression of 22
months was observed for each patient group, and although more
mature data will be required for confirmation, the survival curves
are unlikely to deviate significantly. As expected, differences in
toxicity between the two treatment arms were apparent, with
more haematologic toxicity observed for carboplatin, and more
non-haematologic toxicity for cisplatin. However, no differences
were observed with respect to the incidence of clinically signifi-
cant neurotoxicity. 
Finally, the AGO group trial OVAR-3 randomized patients with
stage IIB–IV disease to receive either cisplatin 75 mg/m2 or
carboplatin AUC 6 in combination with paclitaxel 185 mg/m2,
regardless of tumour bulk Paclitaxel was administered over 3
hours in both arms. After the first analysis with 392 and 384
patients randomized, there was no significant difference in median
progression-free survival between the treatments (73 and 69 weeks
respectively), and this equivalence remains when patients are
stratified as either ‘good risk’ (<1 cm, IIB–III) or ‘poor risk’
(>1 cm, III/IV) (duBois et al, 1999). Once again, the expected
toxicity differences were noted, but here, in contradistinction to
GOG 158, there was more neurotoxicity observed in the cisplatin
arm than the carboplatin arm (grade III/IV, 19% vs 8%). 
Together, these trials suggest that the more convenient carbo-
platin-paclitaxel combination is generally better tolerated than
cisplatin-paclitaxel and appears to be equally efficacious. How-
ever, some concerns remain. The 3-hour infusion of paclitaxel in
combination with carboplatin is still associated with significant
neurotoxicity, and there is still the possibility based on in vitro data
that longer schedules of paclitaxel may be somewhat more effica-
cious as first line therapy (Gianni, 1995). 
Docetaxel (Taxotere®) has demonstrated single-agent efficacy
at least equivalent to paclitaxel, with an overall response rate of
28% in 155 platinum-refractory ovarian cancer patients (Kaye et
al, 1997). Also, clinical studies in breast cancer have confirmed
previous in vitro observations which described incomplete cross-
resistance with paclitaxel (Valero, 1996), and randomized trials in
breast cancer indicate superiority of docetaxel over doxorubicin,
while this has not been seen for paclitaxel (Chan et al, 1997;
Paridaens et al, 1997). There is preliminary evidence of activity
in ovarian cancer patients who have failed prior paclitaxel
(Kavanagh et al, 1999). Moreover, docetaxel is generally delivered
as a convenient 1-hour infusion, suitable for out-patient adminis-
tration. 
The Scottish Gynaecological Cancer Trials Group (SGCTG)
have previously carried out a prospective, non-randomized feasi-
bility study of a cisplatin-docetaxel combination in 100 chemo-
naïve stage Ic–IV ovarian cancer patients (Vasey et al, 1999).
Doses of 75 mg/m2 of both agents in combination appeared to be
feasible, and the delivery of multiple cycles of docetaxel was not
abrogated by fluid retention. However, patient tolerance was rela-
tively poor. Grade III/IV neutropenia was observed in more than
75% patients and appeared to be cumulative, 33% patients were
unable to complete the planned 6 cycles, and increasing the dose
of docetaxel to 85 mg/m2 produced unacceptable haematologic
toxicity and increased risk of morbidity. A response rate of 69%
was observed, but the median progression-free survival for the
group was only 12 months. This may in part be explained by the
poor treatment completion rate due to toxicity. 
The ability of carboplatin to decrease the treatment-related toxi-
city in combination with paclitaxel with no loss of efficacy, led the
SGCTG to initiate a prospective, non-randomized, feasibility
study of docetaxel-carboplatin as first-line therapy for ovarian
cancer patients. The aim was to establish whether patterns of toxi-
city differed from those experienced with paclitaxel-carboplatin,
with particular reference to myelotoxicity and neurotoxicity. A
favourable outcome would be expected to lead to a subsequent
randomized trial. 
METHODS 
Patients 
Eligible women had histologically verified epithelial ovarian
cancer, were over 18 years old and had FIGO stages Ic–IV with or
without successful cytoreductive surgery at staging laparotomy.
Stage Ic disease was limited to patients with malignant cells in
ascitic fluid or peritoneal washings, pre-operative capsular rupture
or surface tumour. Patients had an ECOG performance status of ≤
2, and adequate bone marrow, renal and hepatic function. Written,
informed consent in compliance with the recommendations of the
Declaration of Helsinki was obtained in all cases. 
Patients were ineligible for study entry if they had any prior
treatment with chemotherapy or radiotherapy, or any prior malig-
nancy (except for curatively treated carcinoma in situ of the
uterine cervix or basal cell carcinoma of the skin). Borderline
ovarian tumours or abdominal adenocarcinoma of unknown origin
were excluded, as were patients with clinically significant pleural
effusions or ascites unless confirmed cytologically to be due to
ovarian cancer. Patients were also ineligible if there was a history
of medically significant atrial or ventricular dysrhythmias, conges-
tive heart failure, or documented myocardial infarction within the
6 months preceding study entry. Additional contraindications
included; active infection or serious intercurrent illness that was
judged by the investigators likely to impair the patients’ ability
to receive protocol therapy; a history of prior serious allergicreactions; symptomatic peripheral neuropathy >grade I. Pregnant
or lactating women were ineligible, but potentially fertile women
using adequate contraception were allowed treatment. No patients
with insulin-dependent diabetes mellitus were enrolled. 
Treatment plan and administration 
Docetaxel 60–85 mg/m2 and carboplatin AUC 5–7 were adminis-
tered consecutively on day 1 of a 21 day cycle, for 6 planned
cycles. Carboplatin was dosed according to the Calvert formula
(glomerular filtration rate + 25)  desired AUC (Calvert et al,
1989), where the glomerular filtration rate was measured by
51CrEDTA (Chantler et al, 1969). This dose remained fixed
throughout subsequent cycles, unless de-escalation was required
due to toxicity. Patients who had either a partial response or stable
disease after 6 cycles were allowed to receive further
chemotherapy with 3 cycles of single agent carboplatin, AUC 5–7
depending on the clinician’s preference. The appropriateness of
either second look or interval cytoreductive surgery was deter-
mined on an individual patient basis, as this was not a protocol
requirement. The 5 treatment cohorts are described in Table 1.
Patients were entered into each dose cohort until the first 6 had
completed 2 full treatment cycles. Escalation to the next dose
cohort proceeded if <2 of these 6 patients (and <33% of any other
patients concurrently receiving chemotherapy in that dose cohort)
developed dose-limiting toxicity (DLT). The Maximum Tolerated
Dose (MTD) was defined as the dose level at which ³2 of the first
6 patients followed up for 2 complete cycles (or ³33% of the
patients currently receiving chemotherapy at this dose level) expe-
rienced either (a) complicated or prolonged grade IV neutropenia,
(b) complicated grade IV thrombocytopenia and/or requiring
platelet transfusion, (c) any grade III non-haematologic toxicity
excluding emesis and alopecia. 
Premedication consisted of oral dexamethasone 8 mg b.i.d. for 3
days starting the day before chemotherapy. Docetaxel was recon-
stituted in 250 ml of 5% glucose and administered by intravenous
infusion over 60 minutes. Carboplatin was then administered in
500 ml of 5% glucose over 30–60 minutes. Prophylactic intra-
venous antiemetics (8 mg dexamethasone plus either 3 mg
granisetron (Kytril®, SmithKline Beecham Pharmaceuticals,
Surrey, UK) or 8 mg ondansetron (Zofran®, Glaxo Wellcome Ltd,
Middlesex, UK)) were administered to all patients immediately
prior to the docetaxel infusion. All patients were routinely
prescribed oral domperidone (Motilium®, Sanofi Winthrop Ltd,
Surrey, UK) 20 mg t.i.d.-q.i.d. as required for 5–7 days following
chemotherapy. 
Dose/schedule modifications 
Treatment was administered on d1 of each planned 21 day cycle if
the neutrophils were ³1.5 ´ 109 l21 and platelets ³100 ´ 109 l21;
values less than this necessitated a treatment delay until recovery.
Any delay more than 2 weeks for haematological recovery meant
termination of protocol therapy. Dose reductions were based upon
nadir blood counts. Any grade IV neutropenia that lasted at least 7
days and/or was complicated by fever resulted in a reduction of
docetaxel by 10–15 mg/m2 on all subsequent cycles. Any such
neutropenic events were treated at the time with antibiotics and G-
CSF was added if considered appropriate by the investigator. The
occurrence of neutropenic fever also resulted in prophylactic oral
antibiotics (ciprofloxacin 250 mg b.i.d., day 5–15) being
prescribed for each subsequent treatment cycle. If complicated or
prolonged neutropenia occurred again, despite dose reductions and
prophylactic antibiotics, subsequent cycles were delivered with
subcutaneous G-CSF 300µg d-1 from d5–14 or until the neutrophil
count was > 1.0 ´ 109 and rising. Grade IV thrombocytopenia
requiring platelet transfusion and/or complicated by haemorrhage
resulted in a reduction of the carboplatin dose by 10% in all subse-
quent cycles 
Abnormalities of hepatic function as evidenced by aminotrans-
ferase (AST/ALT) and/or alkaline phosphatase (ALP) elevations
to > grade I during treatment, resulted in the patient being with-
drawn from protocol therapy, and were treated with carboplatin as
a single agent. 
Treatment delays were planned for patients who developed
severe skin toxicity (³ grade III) for a maximum 2 weeks until
recovery to ≤ grade I, when they could be re-treated with a 10–
15 mg/m2 reduction of docetaxel. Mucositis ³ grade II necessitated
a treatment delay of maximum 2 weeks until resolution of lesions,
and a subsequent docetaxel dose reduction as above. No dose
reductions were planned on the basis of docetaxel-induced fluid
retention. The development of grade III/IV neurotoxicity – motor,
sensory or otologic – necessitated termination of protocol therapy. 
Mild hypersensitivity reactions were treated by slowing down
the docetaxel infusion. Severe hypersensitivity reactions were
terminated with appropriate drug therapy (adrenaline, antihista-
mines, corticosteroids, depending upon the severity). Rechallenge
after recovery from a hypersensitivity reaction was allowed if clin-
ically indicated, and was generally done within 3 hours. Later re-
challenges (3–24 hours) were required to be further premedicated
with high dose dexamethasone and chlorpheniramine (Piriton®,
Stafford-Miller Ltd, Herts, UK). Further hypersensitivity reactions
necessitated withdrawal from study. 
Patient evaluation and clinical assessments 
Patients underwent full physical examination including vaginal/
rectal examination. Baseline investigations prior to study entry
included; full blood count and differential white cell count, bio-
chemical profile (including urea, creatinine, sodium, potassium,
calcium, magnesium, AST, ALT, ALP, bilirubin, total protein,
albumen, glucose), CA125, 51CrEDTA measurement of glomerular
filtration rate, chest X-ray, and 12-lead electrocardiogram. The
size and extent of residual disease was documented by CT scan of
abdomen and pelvis. Patients’ weight and ECOG performance
status were noted at baseline. 
During chemotherapy, patients were seen weekly for full blood
count, serum chemistry and documentation of treatment-related
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Table 1 Dose cohorts and treatment delivery 
Cohort Carboplatin  Docetaxel No. patients No. cycles Completed 
(AUC) (mg/m2) registered 6 cycles 
1 5 60 32 169 24 (75%) 
2 5 75 22 122 20 (91%) 
3 6 75 29a 156 23 (82%) 
4 7 75 28b 146 21 (78%) 
5 6 85 30 157 22 (73%) 
a1 patient in this cohort refused study treatment before starting and has been
excluded from all subsequent analyses. b1 patient in this cohort was ineligible
(wrong stage) and has been excluded from all subsequent analyses. toxicity using the National Cancer Institute of Canada Expanded
Common Toxicity Criteria (NCIC-CTC). Prior to each treatment
cycle, patients were weighed and had a full physical examination
plus CA125 estimations. Response to chemotherapy was assessed
after 3 and 6 (and if appropriate, 9) courses of chemotherapy by
the same imaging technique used at baseline. Clinical and radio-
logical tumour response was graded according to standard criteria
(Miller et al, 1981); CA125 responses were graded according to
the schema from Rustin (Rustin et al, 1996). 
Following completion of protocol chemotherapy, patients were
followed up 2-monthly for the first 2 years, 4-monthly to 5 years
and annually thereafter. Pelvic examination was carried out at each
follow-up visit, along with CA125 measurement. CT scans were
carried out if progressive disease was clinically suspected or
CA125 levels began to increase. 
Statistical methods 
Analysis of variance (Anova) techniques were used to compare
cycle 1 nadir neutrophil and platelet counts between cohorts (after
suitable transformations to make the data approximately Normal).
Similarly cumulative haematological toxicity was examined using
repeated measures Anova. Proportions were compared using
Pearson’s chi-square test (unadjusted). All survival times are taken
from the date the patient was registered onto the study.
Progression-free survival is the time from registration to progres-
sion or death (from any cause). Survival curves were determined
using Kaplan-Meier estimates. 
RESULTS 
Patient characteristics and treatment summary 
Between 16 April 1997 and 18 March 1998, 141 patients were
enrolled into this trial by 9 institutions of the Scottish
Gynaecological Cancer Trials Group. One patient in cohort 4 was
wrongly staged and received no treatment, and one patient in
cohort 3 refused study treatment before starting cycle 1. These 2
patients have been excluded from the remainder of the analysis.
Pretreatment characteristics by dose cohort are shown in Table 2.
All patients had ovarian epithelial adenocarcinoma (serous
adenocarcinoma 94 patients/67%; endometrioid carcinoma 21
patients/15%; mucinous adenocarcinoma 9 patients/6%; clear cell
carcinoma 7 patients/5%; others 9 patients/6%). Overall, the
median age was 56 years (range 28–85), 110 patients (79%) were
FIGO stage III/IV at presentation, and 124 (89%) were perfor-
mance status 0–1. There were approximately equal numbers of
optimally (74 patients/54%) vs suboptimally (62/46%) debulked
patients in the group as a whole. In addition, 17 patients had
further surgery; 13 patients had secondary cytoreductive surgery
(8 patients after 6 cycles, 4 after 3, 1 after 9), and 5 patients under-
went a ‘second look’ laparotomy following 6 cycles. One patient
had both secondary cytoreductive surgery and a second look
laparotomy. 
Toxicity summary 
Overall, 750 cycles of docetaxel-carboplatin chemotherapy were
delivered to 139 eligible patients in 5 dose cohorts. 110 patients
received all 6 planned cycles of docetaxel and carboplatin
(completion rate 79%), and only 17 patients (12%) came off
protocol therapy early because of toxicity. 
Haematologic toxicity was observed in all treatment cohorts,
and is presented in Table 3. 104 patients (75%) developed grade IV
neutropenia during the course of their treatment, and the incidence
of grade IV neutropenia and associated neutropenic problems by
treatment cohort is presented in Table 4. The incidence of grade IV
neutropenia ranged from 47% in cohort 1 to 93% in cohort 5, and
was significantly less in cohort 1 compared with the other cohorts
combined (P < 0.001). In addition, there was a linear downward
trend for cycle 1 neutrophil nadir counts over cohorts 1–4 (P =
0.014) or cohorts 1–3 and 5 (P = 0.005). Although the incidence of
grade IV neutropenia was high, there were few episodes of febrile
neutropenia (5 patients/4%) documented. One patient in cohort 4
died with a grade IV neutropenia and unspecified infection during
her second cycle of chemotherapy. Another patient died suddenly
at home on d8 following her first cycle on cohort 5. Unfortunately
no blood counts or post mortem examinations were carried out,
and the patient was therefore classified as a probable toxic death.
22 patients (16%), required dose delays at the beginning of a
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Table 2 Pretreatment characteristics 
Cohort 1 Cohort 2 Cohort 3 Cohort 4 Cohort 5a
(n = 32) (n = 22) (n = 28) (n = 27) (n = 30) 
Col% n Col% n Col%  n Col%  n Col% n
Perf. Status 0 34% 11 45% 10 20% 7 33% 9 62% 18 
1 59% 19 45% 10 64% 18 48% 13 31% 9 
2 3% 1 5% 1 11% 3 19% 5 7% 2 
3 3% 1 5% 1 0% 0 0% 0 0% 0 
Residual diseaseb ≤ 2 cm 52% 16 52% 11 63% 17 41% 11 63% 19 
> 2 cm 46% 15 48% 10 37% 10 59% 16 37% 11 
Stage Ic 3% 1 0% 0 14% 4 7% 2 17% 5 
II 6% 2 18% 4 7% 2 22% 6 7% 2 
III 72% 23 82% 18 68% 19 59% 16 72% 21 
IV 19% 6 0% 0 11% 3 11% 3 3% 1 
Age Median 56 50 57 56 55 
IQ range 48–61 46–59 53–63 49–62 49–60 
Range 32–71 28–74 43–69 28–70 33–85 
a Data not returned on performance status and stage for patient 129 (cohort 5). b Data not available on 3 patients (2 in cohort 1, 1 in cohort 3). treatment cycle as a direct result of unresolved toxicity. There was
evidence of cumulative neutropenia over the first 3 cycles of
chemotherapy in all cohorts with the nadir value of cycle 3 around
40% less than that on cycle 1 (P < 0.001, test for linear trend over
cycles 1–3). On cycles 4–6 nadir levels are roughly consistent. 
Evidence for a platelet-sparing effect was noted for docetaxel-
carboplatin. Despite 51CrEDTA-measured carboplatin AUCs of
5–7, Table 3 demonstrates that only 6 patients (4.2%) developed
grade IV thrombocytopenia during the course of their treatment. 5
patients received prophylactic platelet transfusions (1 in cohort 3,
4 in cohort 4), as this was left to the policy of the individual
hospital. No thrombocytopenic haemorrhages were reported,
although one patient experienced a minor bleed from her
colostomy and received a platelet transfusion. Cohort 4 (carbo-
platin AUC 7) cycle 1 nadir platelet counts were found to be
significantly less than cohorts 1–3 (P < 0.05 for each pairwise
comparison after Bonferroni adjustment). A substantial drop in the
average nadir platelet count of 50 ´ 109 1-1 was demonstrated in all
cohorts between cycles 1 and 2 (P < 0.001). Thereafter, the nadir
count only decreased by around 20 ´ 1091-1 between cycles 2 and
5 (P < 0.001, test for linear trend over cycles 2–5) and actually
appeared to slightly increase on cycle 6. Overall, the incidence of
grade IV thrombocytopenia was not statistically different between
all treatment cohorts (P = 0.19). 
Anaemia was commonly observed, but usually not at significant
levels (grade III, 24 patients/17%; grade IV, 2 patients/1%). The
decision to transfuse packed cells was left to the individual inves-
tigator, and was based upon clinical symptoms in addition to the
haemaglobin level. Only 3 cycles of chemotherapy (0.4%; all in
cohort 5) were delayed because of significant anaemia. 
Significant non-haematologic toxicity was uncommon, and
overall the combination was well tolerated. Fatigue or lethargy
during treatment was reported by over 50% patients, but only 5
patients reported this non-specific symptom at grade III. There
were no statistically significant differences in non-haematologic
toxicity between the 5 treatment cohorts, and this is shown in
Table 5. 
Significant emesis was rare; no patients experienced grade IV
nausea or vomiting, and only 6% (nausea) and 4% (vomiting)
experienced grade III. Severe diarrhoea was observed in only 4
patients, although because of the definition of MTD, this was one
of the toxicities that described the DLT in cohorts 4 and 5.
Constipation was more common, but again only 2 patients
reported grade III toxicity. The routine use of the antiemetic
granisetron (Kytril™) may have contributed to this symptom.
Grade III mucositis was reported by only 1 patient. 
The incidence of significant neurotoxicity was especially low.
Table 5 describes the incidence of all grades of motor and
sensorineural neurotoxicity during the study. Overall, 36 patients
(26%) experienced treatment-related peripheral neuropathy during
the study. This was defined in 28 patients (20%) as grade I, in only
7 patients at grade II (4.6%) and only 1 at grade III (0.7%). No
patients stopped protocol therapy because of neurotoxicity, and
there was no motor toxicity reported > grade I. 
Hypersensitivity reactions to docetaxel were observed in 11
patients (8%), and 4 (3%) were classified as severe. All but 1
patient experienced this reaction on the first or second cycle, and
five patients were withdrawn from protocol therapy and continued
treatment with single agent carboplatin. All other patients were
retreated, with slight schedule modification and further dexam-
ethasone premedication. 
Fluid retention was not a significant clinical problem. Increased
weight gain or mild peripheral oedema that did not require diuretic
therapy was reported for 15 patients (11%). 
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Table 3 Haematological toxicity (worst grade over cycles received) 
Cohort 1 Cohort 2 Cohort 3 Cohort 4 Cohort 5 
(n = 32) (n = 22) (n = 28) (n = 27) (n = 30) 
Grade Col% n Col% n Col% n Col% n Col% n
Neutropenia 3 28% 9 9% 2 21% 6 15% 4 7% 2 
4 47% 15 77% 17 75% 21 82% 22 93% 28 
Leucopenia 3 44% 14 59% 13 54% 15 56% 15 63% 19 
4 0% 0 5% 1 14% 4 22% 6 17% 5 
Thrombocytopenia 3 9% 3 14% 3 14% 4 30% 8 23% 7 
4 0% 0 0% 0 7% 2 11% 3 3% 1 
Anaemia 3 19% 6 9% 2 18% 5 26% 7 13% 4 
4 0% 0 5% 1 0% 0 4% 1 0% 0 
Table 4 Grade IV/complicated neutropenia 
Co1 Co2 Co3 Co4 Co5 Total 
Patients 32 22 28 27 30 139 
Cycles 169 122 156 146 157 750 
Grade IV (overall) 15 (47%) 17 (77%) 21 (75%) 22 (82%) 28 (93%) 103 (74%) 
prolonged >7d 2 (6%) 3 (14%) 2 (7%) 5 (19%) 1 (3%) 13 (9%) 
with fever 0 1 (3%) 2 (7%) 0 2 (7%) 5 (5%) 
dose reductions 1 (6%) 1 (6%) 2 (10%) 3 (14%) 1 (4%) 8 (8%) 
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The Maximum Tolerated Dose (MTD) was reached in both
cohorts 4 and 5. In both these cohorts, 2 of the first 6 patients expe-
rienced dose-limiting toxicities; in cohort 4, grade IV diarrhoea
and a toxic death occurred; in cohort 5 prolonged grade IV
neutropenia and grade III diarrhoea were reported. 
Response and survival 
73 patients were evaluable for clinical or radiological response at
baseline, and 93 were assessable for CA125 response. These results
are presented in Table 6. The overall response rate was 66% (49/74)
with a 95% confidence interval of 54–77%. 75% (70/93) patients
had a CA125 response. Only 9/139 (6%) patients progressed on
chemotherapy, stopping treatment before the planned 6 cycles.
Progression-free survival for the group as a whole is presented in
Figure 1. There is no significant difference in PFS between the
groups. Median follow-up for living patients is 19 months
(minimum 3 months, maximum 30 months). Median progression-
free survival is 16.6 months (95% confidence interval 13.2–19.9
months), and the survival rate at 1 year is 84% (SE = 3%). 
DISCUSSION 
This study describes the first experience of docetaxel and carbo-
platin in combination as the first-line chemotherapy of epithelial
ovarian cancer. Although not a randomized trial, 139 eligible
chemo-naïve patients were treated with this combination, and this
allows some conclusions to be made with regards to its potential
utility and acceptability, particularly bearing in mind previous
experience with paclitaxel and carboplatin. 
The most notable feature of this feasibility study was the
extremely low incidence of clinically significant neurotoxicity,
especially with carboplatin AUCs up to 7 in combination with
docetaxel. No patients were removed from protocol therapy as a
direct result of this side-effect, and troublesome functional
neuronal impairment – CTC grade II/III toxicity – was reported in
less than 6% of all patients. Peripheral sensorineural and motor
toxicity is the principal non-myelogenous toxicity of paclitaxel,
occurring in up to 80% of patients (Kunitoh et al, 1998), and is
dependent upon the cumulative dose and schedule of administra-
tion (Rowinski et al, 1993). As a single agent, docetaxel produces
neuropathy in only 11% of treated patients (New et al, 1996), and
unlike paclitaxel neuropathy, which may manifest early during
treatment, docetaxel-induced neuropathy generally does not
appear until cumulative doses of docetaxel exceeding 600 mg/m2
(Hilkens et al, 1996). The aetiology of taxane-induced neuronal
damage is not completely understood, but is thought to be an effect
on neuronal and Schwann cell microtubules with subsequent
axonal degeneration and demyelination. It is not clear why
docetaxel and paclitaxel differ in the degree of neurotoxicity
produced at otherwise equitoxic doses. However, this study clearly
shows a lower rate of neuropathy than observed in studies of
carboplatin in combination with paclitaxel (Neijt et al, 1996;
duBois et al, 1999; Ozols et al, 1999), and suggests a toxicity
advantage for docetaxel plus carboplatin, which may be important
for longer treatment durations. 
General tolerance to the carboplatin-docetaxel combination was
excellent, as can be evidenced by Table 5, and the high overall
treatment completion rate (Table 1). There were no treatment with-
drawals due to fluid retention, confirming that this earlier form of
Table 5 Non-haematologic toxicity 
Cohort 1 Cohort 2 Cohort 3 Cohort 4 Cohort 5
(n = 22) (n = 27)
(n = 32) (n = 28) (n = 30) 
Grade Col% n Col% n Col% n Col% n Col% n
Nausea 3 13% 4 5% 1 4% 1 7% 2 0% 0 
Vomiting 3 3% 1 5% 1 7% 2 7% 2 0% 0 
Diarrhoea 3 0% 0 0% 0 0% 0 0% 0 7% 2 
4 3% 1 0% 0 0% 0 4% 1 0% 0 
Stomatitis 3 0% 0 0% 0 0% 0 4% 1 0% 0 
Abdominal pain 3 6% 2 0% 0 7% 2 0% 0 0% 0 
4 0% 0 0% 0 4% 1 0% 0 0% 0 
Constipation 3 0% 0 5% 1 0% 0 0% 0 10% 3 
Tiredness/fatigue/lethargy 3 0% 0 5% 1 0% 0 7% 2 7% 2 
Sensory neuropathy 1 13% 4 23% 5 36% 10 19% 5 13% 4 
2 3% 1 9% 2 4% 1 7% 2 3% 1 
3 0% 0 0% 0 4% 1 0% 0 0% 0 
Motor 1 3% 1 5% 1 0% 0 0% 0 0% 0 
Table 6 Response 
Cohort 1 Cohort 2 Cohort 3 Cohort 4 Cohort 5 
Col% Count Col% Count Col% Count Col% Count Col% Count 
CR 23% 5 67% 8 43% 7 31% 5 38% 6 
PR 29% 6 0% 0 25% 4 19% 3 31% 5 
Stable 14% 3 33% 4 13% 2 37% 6 13% 2 
PD 19% 4 0% 0 6% 1 6% 1 13% 2 
CR+PR 61% 11 67% 8 78% 11 53% 8 73% 11 
uneval 14% 3 0% 0 13% 2 6% 1 7% 1 176 PA Vasey et al
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dose-limiting toxicity can be abrogated successfully by a short, 3-
day course of dexamethasone (Docetaxel Investigator’s Brochure,
1999). There were no notable, consistent side-effects due to the
dose and duration of corticosteroids, and in addition, there was no
requirement for routine, prophylactic, intravenous antihypersensi-
tivity medication. Severe hypersensitivity was documented in only
3% of patients, a figure comparable to that documented for do-
cetaxel given as a single agent. 
CTC grade III or IV neutropenia occurred in 90% of all patients
over the 5 treatment cohorts. That this level of myelosuppression
was not accompanied by a higher rate of sepsis is attributable to
the generally short duration of neutropenia and lack of significant,
accompanying toxicities such as mucositis or diarrhoea, which act
as reservoirs for bacterial infection. However, it must be noted that
there was at least one (and possibly another) drug-related fatality.
Because of the dose-limiting toxicities experienced by patients in
cohorts 4 and 5, cohort 2 (carboplatin AUC 5 and docetaxel 75
mg/m2) is thought to represent the best combination, offering a
balance between efficacy and toxicity. At these doses, grade III or
IV neutropenia was observed in 86% of treated patients (19/22).
This is only slightly more than we have observed with the combi-
nation of a 3 hour 175 mg/m2 paclitaxel infusion and carboplatin
AUC 5, which produces grade III or IV neutropenia in approxi-
mately 75% patients (author, unpublished data from SCOTROC
trial). The incidence of myelosuppression in this trial with pacli-
taxel-carboplatin is higher than most reports, but probably reflects
the fact that these patients all had weekly haematology performed. 
Efficacy and survival were not primary endpoints for this study,
as phase II-type data such as this is not directly comparable with
survival data obtained from prospective, randomized trials.
However, the low rate of on-study progressive disease and a
median progression-free survival of greater than 16 months for this
non-selected patient population is indicative of significant activity,
at least comparable to similar data from early trials with paclitaxel-
platinum combinations using both cisplatin and carboplatin.
However, in order to truly determine whether the combination of
docetaxel and carboplatin can be recommended as routine first-
line therapy for epithelial ovarian cancer, prospective randomized
comparison with paclitaxel and carboplatin is warranted.
In October 1998, the first patient was entered into the SCOTROC
Trial (Scottish Randomised Trial in Ovarian Cancer),
which randomizes patients with stage Ic–IV ovarian or primary
peritoneal cancers to receive either docetaxel or paclitaxel in
combination with carboplatin. This international study completed
recruitment in May 2000 with 1077 patients randomized, and first
survival and toxicity results will be available in May 2001. 
Further studies are in progress looking at the possibility of
combining other, non-cross resistant agents with carboplatin-
docetaxel. There is evidence from two meta-analyses for the addi-
tional benefit of incorporating an anthracycline into combination
chemotherapy regimens for advanced ovarian cancer. 4 random-
ized trials have compared an anthracycline-containing regimen
(‘CAP’) with a non-anthracycline containing regimen (‘CP’). All
these trials demonstrated a slight advantage, albeit not achieving
statistical significance, for CAP with regards to survival. However,
more recently, a published overview of 2 large meta-analyses
(from the AOCTG and OCMP groups) using data from >1700
untreated patients demonstrated that the addition of the anthracy-
cline significantly improved survival (HR 0.85, P = 0.003) (A’hern
and Gore, 1995). The most common anthracycline in current usage
is doxorubicin (Adriamycin), however, epirubicin (Pharmorubi-
cin) is known to have essentially the same spectrum of activity,
with less cardiotoxicity, and therefore has a more favourable toxi-
city profile. Furthermore, epirubicin 60 mg/m2 has been added to
the combination of paclitaxel 175 mg/m2 and Carboplatin AUC 7,
with a high response rate and manageable toxicities (Hill et al,
1997). In addition, the AGO group have now completed a random-
ized trial comparing carboplatin-paclitaxel with carboplatin-pacli-
taxel-epirubicin as first line treatment. The addition of epirubicin
to carboplatin-docetaxel as first-line chemotherapy was the subject
of a recently completed feasibility study (Vasey et al, 1999 and
manuscript in preparation). Utilizing epirubicin doses of 50–60
mg/m2 in combination on day 1 of a 3 week cycle proved to be
very myelosuppressive, with cycle delays and dose reductions
required in most patients. The recommended dose for this combi-
nation is carboplatin reduced to AUC 4 plus docetaxel 75 mg/m2
and epirubicin 50 mg/m2. 
In conclusion, this dose-finding study has demonstrated that
docetaxel and carboplatin can be combined safely and with signif-
icant efficacy as first line chemotherapy for advanced epithelial
ovarian cancer. Doses recommended are carboplatin AUC 5 (if
glomerular filtration rate measured by 51CrEDTA) or 6 (if calcu-
lated using the Cockcroft-Gault formula) in combination with
docetaxel 75 mg/m2. Although myelosuppression is commonly
observed, sepsis is rare and neither prophylactic antibiotics nor
growth factors are required routinely. Moreover, the incidence
of significant neuropathy for patients treated with docetaxel-
carboplatin is very low, and may confer a significant toxicity
advantage over paclitaxel-carboplatin for this patient population. 
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